

# Gabriel G Malouf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8869303/publications.pdf>

Version: 2024-02-01

77  
papers

3,041  
citations

117453

34  
h-index

168136

53  
g-index

88  
all docs

88  
docs citations

88  
times ranked

5291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. <i>Annals of Oncology</i> , 2010, 21, 1834-1838.	0.6	188
2	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. <i>Oncotarget</i> , 2014, 5, 9864-9876.	0.8	188
3	Histone deacetylase inhibitors as anti-neoplastic agents. <i>Cancer Letters</i> , 2009, 280, 192-200.	3.2	146
4	NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1067-1074.	0.3	143
5	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes. <i>Clinical Cancer Research</i> , 2014, 20, 4129-4140.	3.2	117
6	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016, 70, 348-357.	0.9	111
7	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. <i>Scientific Reports</i> , 2013, 3, 2687.	1.6	104
8	Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors. <i>Journal of Urology</i> , 2011, 185, 24-29.	0.2	91
9	Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. <i>Cancer Research</i> , 2016, 76, 1494-1505.	0.4	88
10	Long non-coding RNAs in genitourinary malignancies: a whole new world. <i>Nature Reviews Urology</i> , 2019, 16, 484-504.	1.9	80
11	Genomic Heterogeneity of Translocation Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4673-4684.	3.2	77
12	Characterization of long non-coding RNA transcriptome in clear cell renal cell carcinoma by next-generation deep sequencing. <i>Molecular Oncology</i> , 2015, 9, 32-43.	2.1	75
13	Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. <i>Genome Biology</i> , 2013, 14, R144.	13.9	74
14	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	7.7	74
15	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. <i>Scientific Reports</i> , 2017, 7, 41960.	1.6	73
16	Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. <i>ELife</i> , 2016, 5, .	2.8	71
17	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. <i>BJU International</i> , 2017, 120, 782-792.	1.3	68
18	Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. <i>European Journal of Cancer</i> , 2013, 49, 1324-1334.	1.3	67

#	ARTICLE	IF	CITATIONS
19	Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. <i>Histopathology</i> , 2017, 70, 1089-1097.	1.6	65
20	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
21	Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 397-407.	1.9	61
22	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3059-3082.	1.3	61
23	Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. <i>Hepatology</i> , 2014, 59, 2228-2237.	3.6	57
24	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. , 2018, 6, 159.		56
25	Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.	2.5	52
26	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2016, 22, 6236-6246.	3.2	47
27	Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. <i>Cancer</i> , 2012, 118, 4981-4990.	2.0	44
28	Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny. <i>Cell Reports</i> , 2018, 25, 811-821.e5.	2.9	44
29	Impact of adjuvant treatment modalities on the management of patients with stages Iâ€“II endometrial stromal sarcoma. <i>Annals of Oncology</i> , 2010, 21, 2102-2106.	0.6	43
30	Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. <i>International Journal of Gynecology and Obstetrics</i> , 2013, 122, 57-61.	1.0	41
31	<i>NSD1</i> Inactivation and <i>SETD2</i> Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. <i>Cancer Research</i> , 2017, 77, 4835-4845.	0.4	40
32	The epigenome of AML stem and progenitor cells. <i>Epigenetics</i> , 2013, 8, 92-104.	1.3	38
33	Cancer subtypes classification using long non-coding RNA. <i>Oncotarget</i> , 2016, 7, 54082-54093.	0.8	38
34	Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas. <i>Scientific Reports</i> , 2016, 6, 30988.	1.6	37
35	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017, 72, 974-983.	0.9	36
36	Comprehensive integrative profiling of upper tract urothelial carcinomas. <i>Genome Biology</i> , 2021, 22, 7.	3.8	31

#	ARTICLE	IF	CITATIONS
37	Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 191-200.	0.9	28
38	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 9-21.	0.7	27
39	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. <i>Cancers</i> , 2020, 12, 99.	1.7	23
40	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
41	Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 8540.	1.6	21
42	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	1.6	21
43	Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. <i>Oncotarget</i> , 2015, 6, 39865-39876.	0.8	20
44	Evaluating the prognostic potential of the Ki67 proliferation index and tumour-infiltrating lymphocytes in olfactory neuroblastoma. <i>Histopathology</i> , 2019, 75, 853-864.	1.6	18
45	Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. <i>Epigenetics</i> , 2015, 10, 872-881.	1.3	17
46	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
47	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. <i>Oral Oncology</i> , 2019, 95, 79-86.	0.8	15
48	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail. <i>Journal of Oncology Practice</i> , 2016, 12, 412-420.	2.5	11
49	Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. <i>Oncologist</i> , 2019, 24, 980-988.	1.9	11
50	French Multidisciplinary Approach for the Treatment of MSK Tumors. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 310-322.	0.4	10
51	Efficacy of additional chemotherapy following failure of currently approved therapies in patients with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-274.	0.8	10
52	Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 409-418.	0.3	10
53	Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1769-1778.e2.	0.3	9
54	Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. <i>Cancers</i> , 2021, 13, 4341.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 cases. <i>Histopathology</i> , 2022, 80, 928-945.	1.6	8
56	Oncogenic viruses: Lessons learned using next-generation sequencing technologies. <i>European Journal of Cancer</i> , 2016, 61, 61-68.	1.3	7
57	Papillary Renal Cell Carcinoma: A Family Portrait. <i>European Urology</i> , 2018, 73, 79-80.	0.9	6
58	Effect of SMARCB1 deficiency in renal medullary carcinoma (RMC) on genes associated with nucleosome assembly and telomere organization.. <i>Journal of Clinical Oncology</i> , 2018, 36, 614-614.	0.8	3
59	Metabolic Derangements in Succinate Dehydrogenase Mutated Renal-Cell Carcinomas: More Than Meets the Eye?. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	1.5	2
60	Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis. <i>Clinical Nuclear Medicine</i> , 2018, 43, 698-699.	0.7	2
61	Prognostic impact of percentage of squamous differentiation in patients with nonbilharzial squamous cell carcinoma and transitional cell carcinoma treated with radical cystectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 498-498.	0.8	2
62	Reply to "Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas". <i>Histopathology</i> , 2017, 71, 836-837.	1.6	1
63	Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. <i>European Urology</i> , 2017, 71, 415-416.	0.9	1
64	Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target.. <i>Journal of Clinical Oncology</i> , 2016, 34, 571-571.	0.8	1
65	Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4575-4575.	0.8	1
66	Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4571-4571.	0.8	1
67	Classifying endometrioid endometrial cancer by long noncoding RNA profiling: Indication of prognosis and therapy selection.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11064-11064.	0.8	0
68	Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations.. <i>Journal of Clinical Oncology</i> , 2016, 34, 537-537.	0.8	0
69	Translocation Renal Cell Carcinomas. , 2016, , 41-52.		0
70	DNA methylation signature to define cell ontogeny of renal cell carcinomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 536-536.	0.8	0
71	Assessment of tumor-infiltrating lymphocytes and immune-checkpoints expression in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3608-3608.	0.8	0
72	Comprehensive genomic characterization of clear-cell renal cell carcinomas with sarcomatoid dedifferentiation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16076-e16076.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients.. Journal of Clinical Oncology, 2016, 34, e16111-e16111.	0.8	0
74	Transcriptomic profiling of collecting duct carcinoma to reveal metabolic and immune aberrations.. Journal of Clinical Oncology, 2016, 34, 4572-4572.	0.8	0
75	Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target.. Journal of Clinical Oncology, 2016, 34, 4566-4566.	0.8	0
76	DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny.. Journal of Clinical Oncology, 2016, 34, 4512-4512.	0.8	0
77	Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethylstilbestrol in castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, e581-e581.	0.8	0